Mark Berger
Directeur Technique/Scientifique/R&D chez GENPREX, INC.
Fortune : 3 287 $ au 30/06/2024
Profil
Mark S.
Berger is currently the Chief Medical Officer at Genprex, Inc. He previously held positions as the Senior Director-Oncology Clinical Development at Wyeth Pharmaceuticals LLC, Group Director-Clinical Oncology at GSK Plc, Principal at the University of Pennsylvania, Vice President-Clinical Development at Gemin X Pharmaceuticals US, Inc., Chief Medical Officer at Deciphera Pharmaceuticals LLC, Senior Vice President-Clinical Research at Kadmon Corp.
LLC, and Chief Medical Officer at Actinium Pharmaceuticals, Inc. Dr. Berger completed his undergraduate degree at Wesleyan University and obtained his doctorate from The University of Virginia School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENPREX, INC.
0,08% | 25/04/2024 | 1 744 ( 0,08% ) | 3 287 $ | 30/06/2024 |
Postes actifs de Mark Berger
| Sociétés | Poste | Début |
|---|---|---|
| GENPREX, INC. | Directeur Technique/Scientifique/R&D | 27/09/2021 |
Anciens postes connus de Mark Berger
| Sociétés | Poste | Fin |
|---|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 24/09/2021 |
Kadmon Corp. LLC
 Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Directeur Technique/Scientifique/R&D | 01/01/2017 |
Deciphera Pharmaceuticals LLC
 Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Directeur Technique/Scientifique/R&D | 01/09/2013 |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 01/06/2011 |
| GSK PLC | Corporate Officer/Principal | 01/02/2007 |
Formation de Mark Berger
| Wesleyan University | Undergraduate Degree |
| The University of Virginia School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GSK PLC | Health Technology |
| ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
| GENPREX, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
